newsfilter
← Latest News
Business Wire·

Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers

  • IAM1363, a brain-penetrant HER2 tyrosine kinase inhibitor discovered using Iambic's AI platform, progressed from initiation to clinical development in approximately two years.
  • Updated data presented at ESMO 2026 shows the drug was well-tolerated with low rates of Grade 3 or higher treatment-related adverse events, serious adverse events, & dose modifications.
  • More than half of participants dosed at 960 mg remain on study, with some maintaining treatment beyond one year.
  • Intracranial responses were observed in three participants with HER2-positive breast cancer who had previously received T-DXd & tucatinib, including one patient with over 50 brain metastases.
  • In participants with targetable HER2 alterations dosed at ≥960 mg QD, the best overall response rate was 36% (partial response) & 38% showed stable disease.
  • Intracranial activity showed a 41% partial response rate & 55% stable disease rate in the evaluable cohort of 22 participants.
  • The trial included 122 participants, with 61% having received prior T-DXd & 36% prior tucatinib, across tumor types including breast cancer, NSCLC, & renal cell cancer.
  • Common treatment-emergent adverse events included diarrhea (59%), nausea (53%), & vomiting (49%), with no Grade 4 or 5 treatment-related adverse events reported.
  • The ongoing Phase 1/1b trial (NCT06253871) is currently enrolling in Parts 3 (monotherapy expansion) & Part 4 (combination cohorts) at sites in the U.S., Europe, & Asia.